15.56
-0.19 (-1.21%)
| Previous Close | 15.75 |
| Open | 15.73 |
| Volume | 162,588 |
| Avg. Volume (3M) | 575,537 |
| Market Cap | 5,646,988,800 |
| Price / Earnings (Forward) | 13.42 |
| Price / Sales | 0.900 |
| Price / Book | 0.670 |
| 52 Weeks Range | |
| Earnings Date | 19 Feb 2025 |
| Profit Margin | -6.62% |
| Operating Margin (TTM) | 6.72% |
| Diluted EPS (TTM) | -0.900 |
| Quarterly Revenue Growth (YOY) | 9.10% |
| Total Debt/Equity (MRQ) | 75.43% |
| Current Ratio (MRQ) | 1.60 |
| Operating Cash Flow (TTM) | 232.00 M |
| Levered Free Cash Flow (TTM) | 188.38 M |
| Return on Assets (TTM) | 0.96% |
| Return on Equity (TTM) | -4.53% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Bearish | Mixed |
| Medical Instruments & Supplies (Global) | Bearish | Mixed | |
| Stock | Bausch + Lomb Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -3.5 |
| Insider Activity | -3.0 |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -1.60 |
|
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Core |
| % Held by Insiders | 88.18% |
| % Held by Institutions | 10.25% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Maple Rock Capital Partners Inc. | 31 Dec 2024 | 3,171,053 |
| Alberta Investment Management Corp | 31 Dec 2024 | 3,008,193 |
| Goldentree Asset Management Lp | 31 Dec 2024 | 1,732,197 |
| Whitebox Advisors Llc | 31 Dec 2024 | 1,443,101 |
| King Street Capital Management, L.P. | 31 Dec 2024 | 1,136,321 |
| Mangrove Partners Im, Llc | 31 Dec 2024 | 1,059,133 |
| Laurion Capital Management Lp | 31 Dec 2024 | 1,033,880 |
| Empyrean Capital Partners, Lp | 31 Dec 2024 | 931,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 17.00 (RBC Capital, 9.25%) | Buy |
| 17.00 (B of A Securities, 9.25%) | Sell | |
| Median | 15.00 (-3.60%) | |
| Low | 12.00 (Morgan Stanley, -22.88%) | Hold |
| 12.00 (Wells Fargo, -22.88%) | Hold | |
| Average | 14.56 (-6.43%) | |
| Total | 3 Buy, 4 Hold, 1 Sell | |
| Avg. Price @ Call | 12.35 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 06 May 2025 | 12.00 (-22.88%) | Hold | 11.56 |
| HC Wainwright & Co. | 02 May 2025 | 15.00 (-3.60%) | Buy | 11.56 |
| 21 Feb 2025 | 20.00 (28.53%) | Buy | 15.75 | |
| Citigroup | 01 May 2025 | 13.00 (-16.45%) | Hold | 11.56 |
| Evercore ISI Group | 01 May 2025 | 15.50 (-0.39%) | Buy | 11.56 |
| Wells Fargo | 01 May 2025 | 12.00 (-22.88%) | Hold | 11.56 |
| 28 Mar 2025 | 15.00 (-3.60%) | Hold | 14.13 | |
| RBC Capital | 04 Apr 2025 | 17.00 (9.25%) | Buy | 12.11 |
| 20 Feb 2025 | 18.00 (15.68%) | Buy | 15.89 | |
| Stifel | 03 Apr 2025 | 15.00 (-3.60%) | Hold | 12.99 |
| B of A Securities | 20 Feb 2025 | 17.00 (9.25%) | Sell | 15.89 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |